A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract

Braybrooke, J. P., O'Byrne, Kenneth J., Saunders, M. P., Propper, D. J., Salisbury, A. J., Boardman, P., Taylor, M., Ganesan, T. S., Talbot, D. C., & Harris, A. L. (1997) A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. Annals of Oncology, 8(3), pp. 294-296.

View at publisher (open access)

Abstract

Background: Mitomycin C and etoposide have both demonstrated activity against gastric carcinoma. Etoposide is a topoisomerase II inhibitor with evidence for phase-specific and schedule-dependent activity.

Patients and method. Twenty-eight consecutive patients with advanced upper gastrointestinal adenocarcinoma were treated with intravenous (i.v.) bolus mitomycin C 6 mg/m2 on day 1 every 21 days to a maximum of four courses. Oral etoposide capsules 50 mg b.i.d. (or 35 mg b.i.d. liquid) were administered days 1 to 10 extending to 14 days in subsequent courses if absolute neutrophil count >1.5 x 109/l on day 14 of first course, for up to six courses.

Results: Twenty-six patients were assessed for response of whom 12 had measurable disease and 14 evaluable disease. Four patients had a documented response (one complete remission, three partial remissions) with an objective response rate of 15% (95% confidence interval (95% CI) 4%-35%). Eight patients had stable disease and 14 progressive disease. The median survival was six months. The schedule was well tolerated with no treatment-related deaths. Nine patients experienced leucopenia (seven grade II and two grade III). Nausea and vomiting (eight grade II, one grade III), fatigue (eight grade II, two grade III) and anaemia (seven grade II, two grade III) were the predominant toxicities.

Conclusion: This out-patient schedule is well tolerated and shows modest activity in the treatment of advanced upper gastrointestinal adenocarcinoma. Further studies using protracted schedules of etoposide both orally and as infusional treatment should be developed.

Impact and interest:

6 citations in Scopus
Search Google Scholar™
7 citations in Web of Science®

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 64846
Item Type: Journal Article
Refereed: Yes
Additional Information: Articles free to read on journal website after 12 months
Additional URLs:
Keywords: advanced gastric cancer, mitomycin C, oral etoposide, dexamethasone, etoposide, metoclopramide, adenocarcinoma, adult, aged, anemia, article, clinical article, clinical trial, esophagus carcinoma, fatigue, female, human, intravenous drug administration, leukopenia, male, nausea, oral drug administration, phase 2 clinical trial, priority journal, stomach carcinoma, vomiting, Administration, Oral, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Drug Administration Schedule, Esophageal Neoplasms, Humans, Injections, Intravenous, Middle Aged, Mitomycin, Stomach Neoplasms, Treatment Outcome
DOI: 10.1023/A:1008295926603
ISSN: 0923-7534
Divisions: Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
Copyright Owner: Copyright 1997 Oxford University Press
Deposited On: 27 Nov 2013 06:06
Last Modified: 27 Jan 2015 05:12

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page